These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Preparation of conjugates of oligodeoxynucleotides and lipid structures and their interaction with low-density lipoprotein. Rump ET; de Vrueh RL; Sliedregt LA; Biessen EA; van Berkel TJ; Bijsterbosch MK Bioconjug Chem; 1998; 9(3):341-9. PubMed ID: 9576808 [TBL] [Abstract][Full Text] [Related]
5. Hepatobiliary elimination of bile acid-modified oligodeoxynucleotides in Wistar and TR- rats: evidence for mrp2 as carrier for oligodeoxynucleotides. Lischka K; Starke D; Failing K; Herling A; Kramer W; Petzinger E Biochem Pharmacol; 2003 Aug; 66(4):565-77. PubMed ID: 12906921 [TBL] [Abstract][Full Text] [Related]
6. Thermodynamic studies on hairpin forming antisense-oligodeoxynucleotides directed against hepatitis C virus RNA. Lehmann TJ; Eisenhardt S; Engels JW Nucleosides Nucleotides; 1999; 18(6-7):1689-91. PubMed ID: 10474247 [TBL] [Abstract][Full Text] [Related]
7. Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation. Alt M; Eisenhardt S; Serwe M; Renz R; Engels JW; Caselmann WH Eur J Clin Invest; 1999 Oct; 29(10):868-76. PubMed ID: 10583429 [TBL] [Abstract][Full Text] [Related]
8. Synthetic nucleosides and nucleotides. 37. Antisense oligodeoxynucleotides bearing 5-(phenylethyl)-2'-deoxyuridylate at the 3'-terminus: exonuclease-resistant molecule with natural phosphodiester backbone. Kawaguchi T; Yamaguchi T; Tanaka S; Tashiro Y; Saneyoshi M J Pharm Sci; 1996 Aug; 85(8):815-8. PubMed ID: 8863269 [TBL] [Abstract][Full Text] [Related]
9. Preparation and evaluation of tumor-targeting peptide-oligonucleotide conjugates. Mier W; Eritja R; Mohammed A; Haberkorn U; Eisenhut M Bioconjug Chem; 2000; 11(6):855-60. PubMed ID: 11087334 [TBL] [Abstract][Full Text] [Related]
10. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Vidalin O; Major ME; Rayner B; Imbach JL; Trépo C; Inchauspé G Antimicrob Agents Chemother; 1996 Oct; 40(10):2337-44. PubMed ID: 8891141 [TBL] [Abstract][Full Text] [Related]
11. Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay. Seki M; Honda Y J Biochem; 1995 Dec; 118(6):1199-204. PubMed ID: 8720135 [TBL] [Abstract][Full Text] [Related]
12. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187 [TBL] [Abstract][Full Text] [Related]
13. Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C. Caselmann WH; Eisenhardt S; Alt M Intervirology; 1997; 40(5-6):394-9. PubMed ID: 9675643 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of 4'-C-(Aminoethyl)thymidine and 4'-C-[(N-Methyl)aminoethyl] Thymidine Nucleosides to Enhance DNA Stability. Chandela A; Ueda H; Ueno Y Curr Protoc; 2022 Sep; 2(9):e501. PubMed ID: 36073858 [TBL] [Abstract][Full Text] [Related]
16. Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication. Lavigne C; Yelle J; Sauvé G; Thierry AG AAPS PharmSci; 2001; 3(1):E7. PubMed ID: 11741258 [TBL] [Abstract][Full Text] [Related]